Thromboprophylaxis in outpatients with COVID-19: a safe bet or tilting at windmills?
Minerva Cardiol Angiol
.
2022 Feb;70(1):1-4.
doi: 10.23736/S2724-5683.21.05914-7.
Epub 2021 Oct 29.
Authors
John G Rizk
1
,
Giuseppe Lippi
2
,
Youssef Rizk
3
Affiliations
1
Arizona State University, Edson College, Phoenix, AZ, USA -
[email protected]
.
2
Section of Clinical Biochemistry, University of Verona, Verona, Italy.
3
Division of Family Medicine, Department of Internal Medicine, St. John's Hospital, Lebanese American University Medical Center, Beirut, Lebanon.
PMID:
34713682
DOI:
10.23736/S2724-5683.21.05914-7
No abstract available
MeSH terms
Anticoagulants / adverse effects
COVID-19* / prevention & control
Humans
Outpatients
SARS-CoV-2
Venous Thromboembolism* / prevention & control
Substances
Anticoagulants